Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CCR5 inhibitors: up and coming new agents.

BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation - 1 Jan 2007

O'Neal Reilly

Abstract excerpt

A new class of antiretroviral drugs came on the scene in 2003 with the approval of the first entry inhibitor, enfuvirtide (T-20, Fuzeon). Considerable research has been directed toward discovery of additional drugs that target the cell-entry stage of HIV replication, and CCR5 inhibitors--agents t...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to CCR5 Receptor Antagonists
Share to HIV Fusion Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperazines

Share to Pyrimidines

Share to Receptors, CCR5

Share to Viral Load

Share to Virus Replication

Source

Identifiers

PMID: 17489112

Genes

CCR5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-17489112-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CCR5 inhibitors: up and coming new agents.PMID 17489112Read ↗

Enfuvirtide: the first HIV fusion inhibitorSemantic proximity Read ↗

HIV entry inhibitors: mechanisms of action and resistance pathwaysSemantic proximity Read ↗

Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.Semantic proximity Read ↗

Development of Anti-HIV Therapeutics: From Conventional Drug Discovery to Cutting-Edge TechnologySemantic proximity Read ↗

HIV entry inhibitorsSemantic proximity Read ↗

Resistance to enfuvirtide, the first HIV fusion inhibitor.Semantic proximity Read ↗

CKR-5--understanding the news.Semantic proximity Read ↗

CCR5-edited gene therapies for HIV cure: Closing the door to viral entry.Semantic proximity Read ↗

“Old Dogs with New Tricks”: exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targetsSemantic proximity Read ↗

The Expanding Therapeutic Perspective of CCR5 BlockadeSemantic proximity Read ↗

Basic science discovery: opening the door on HIV.Semantic proximity Read ↗

Small-Molecule Antagonists of CCR5 and CXCR4: A Promising New Class of Anti-HIV-1 DrugsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.